Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01958528 · ClinicalTrials.gov registry record
Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM
A clinical trial of a Diagnosis of MGUS or SMM by IMWG Criteria, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT01958528 is a study of a Diagnosis of MGUS or SMM by IMWG Criteria that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01958528, a study of a Diagnosis of MGUS or SMM by IMWG Criteria, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to collect blood and bone marrow samples from patients with SM and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed for 2 years. The primary objective of this study is to evaluate CMMCs as a biomarker to detect patients at high risk of progression to multiple myeloma in patients with MGUS and SMM.
Conditions Studied
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-05-23 |
| Est. Completion | 2019-01-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01958528
The ClinicalTrials.gov registry entry for NCT01958528 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with a Diagnosis of MGUS or SMM by IMWG Criteria appearing as the primary indexed condition, and to 0 interventions.
NCT01958528 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01958528 about?
NCT01958528 is a clinical study titled "Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM". This is a prospective study to collect blood and bone marrow samples from patients with SM and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed for 2 years. The primary objective of this study is to evaluate CMMCs as a biomarker to detect patients at high risk...
What is the current status of trial NCT01958528?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2013-05-23. Estimated completion is 2019-01-22.
What conditions does trial NCT01958528 study?
This clinical trial studies the following conditions: a Diagnosis of MGUS or SMM by IMWG Criteria.
Who is sponsoring clinical trial NCT01958528?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01958528 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.